Difference in five-year mortality decreased between those entering HIV care and matched population during 1999 to 2017
WEDNESDAY, July 7, 2021 (HealthDay News) — Persons entering HIV care have elevated mortality compared with a matched U.S. population, but the difference has decreased over time, according to a study published online July 6 in the Annals of Internal Medicine.
Jessie K. Edwards, Ph.D., from the University of North Carolina at Chapel Hill, and colleagues examined the extent to which mortality among persons entering HIV care is elevated over mortality among matched individuals from the general U.S. population, and they assessed trends in this difference over time. Data were included for 82,766 adults entering HIV clinical care between 1999 and 2017 and a calendar time-, age-, sex-, race/ethnicity-, and county-matched subset of the U.S. population.
The researchers found that five-year mortality was 10.6 percent among persons entering HIV care and 2.9 percent among the matched U.S. population (difference, 7.7 percent). There was a decrease observed in this difference over time, from 11.1 to 2.7 percent among those entering care during 1999 to 2004 and 2011 to 2017, respectively.
“Understanding differences in mortality between persons entering HIV care and the matched U.S. population is critical to monitor opportunities to improve care. Although these differences have decreased dramatically in the era of modern treatments, gaps remain,” the authors write. “These gaps could reflect the effects of prolonged immunodeficiency in persons who present late to care or persistent immune activation and subsequent end-stage chronic diseases even among those who are successfully treated.”
Abstract/Full Text (subscription or payment may be required)
FDA Could Ease Blood Donation Rules for Gay Men
Another Significant HIV Vaccine Trial Fails
Women Experiencing Intimate Partner Violence More Likely to Contract HIV
Cognitive Behavioral Intervention Ups ART Adherence in Adolescents, Young Adults
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Youth Suicide Risk Linked to Community Firearm Violence
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus
Therapies Compared for Newly Diagnosed Multiple Sclerosis